Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OIP5-AS1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Topical
01
Overview
OIP5-AS1 small interfering RNA (siRNA) is a synthetic double-stranded RNA molecule designed to silence the expression of the long non-coding RNA (lncRNA) OIP5-AS1. In the context of rheumatoid arthritis (RA) research, OIP5-AS1 has been identified as a key regulator of the miR-410-3p/Wnt7b signaling axis. By knocking down OIP5-AS1, this siRNA inhibits the excessive proliferation of fibroblast-like synoviocytes (FLS) and modulates the Wnt/beta-catenin signaling pathway, which is typically overactive in RA pathogenesis. It is primarily utilized as a research tool to investigate molecular mechanisms and validate OIP5-AS1 as a potential therapeutic target for autoimmune and inflammatory diseases.
- Other names
- siRNA targeting OIP5-AS1OIP5-AS1-siRNAOIP-5-AS1-siRNAOIP 5-AS1-siRNAOIP5 antisense RNA 1 siRNAOIP-5 antisense RNA 1 siRNAOIP 5 antisense RNA 1 siRNA
02
Targets
OIP5-AS1 (OIP5 antisense RNA 1)
Beyond the preview
Go deeper on OIP5-AS1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OIP5-AS1 small interfering RNA.